NCT06674109 (SAVE-Care) is a Phase 4 clinical trial of Empagliflozin 10 mg in Gout and Hyperuricemia, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT06674109?

NCT06674109 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT06674109?

Interventions in NCT06674109: Empagliflozin 10 mg, Placebo.

What condition does NCT06674109 study?

NCT06674109 studies Gout and Hyperuricemia.

Is NCT06674109 still recruiting?

NCT06674109 is currently not yet recruiting. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06674109: SAVE-Care

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Not yet recruiting Phase 4 Last updated 30 March 2026

What this trial tests

Phase 4 trial testing Empagliflozin 10 mg in Gout and Hyperuricemia in 60 participants. Not yet recruiting.

Timeline

30 April 2026

Primary endpoint
28 February 2028

28 February 2028

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	30 April 2026
Primary completion	28 February 2028
Estimated completion	28 February 2028

Drugs / interventions tested

Empagliflozin 10 mg — full drug profile →
Placebo

Conditions studied

Gout and Hyperuricemia — all drugs for Gout and Hyperuricemia →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 80, any sex, with Gout and Hyperuricemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \[hsCRP\] and interleukin 6 \[IL-6\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis.
Yang S, Hu Q, Liu K, Xiao B, et al · · 2025 · cited 3× · PMID 40612743 · DOI 10.3389/fphar.2025.1551390

Verify or expand the search:

Other trials of Empagliflozin 10 mg

Trials testing the same drug.

NCT06818305 — Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in · Phase 2 · terminated
NCT06846411 — The EMPA-FIT Study · Phase 4 · recruiting
NCT05905965 — Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment · Phase 3 · recruiting
NCT06632561 — Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus · Phase 4 · completed
NCT03087773 — Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction · Phase 3 · completed

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06674109 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06674109.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing